Skip to content

PP&E (Net) at other companies

Biogen logo
BiogenBIIB
$3.02B-3.7%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
$7.4M-17.7%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$52.74M-11.3%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$23.68M+312%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$994K-19.8%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$5.3M-17.9%

Other financials

Income statement

See full
Revenue-
Operating income-$102.0M-32.3%
Net income-$105.5M-41.2%
EPS (diluted)-$0.83-23.9%

Balance sheet

See full
Cash & equivalents$430.5M+212%
Total debt$205.7M+226%
Total equity$276.0M-11.6%
Total assets$535.3M+31.3%

Cash flow

See full
Operating cash flow-$82.1M-4.4%
CapEx$68.0K-74.9%
Free cash flow-$82.2M-4.1%

Valuation

See full
Market cap$5.67B+85.5%

Profitability

See full
Operating margin-231.8%
Net margin-236.9%
FCF margin-309.1%

Returns & leverage

See full
Return on equity-138.9%+60.1pp
Debt / equity0.7×+0.5×
Current ratio8.6×-1.6×

Where this comes from

Reported directly by Scholar Rock in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scholar Rock's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scholar Rock's PP&E (net)?
Scholar Rock (SRRK) reported PP&E (net) of $1.44M in Q1 2026.
How has Scholar Rock's PP&E (net) changed year-over-year?
Scholar Rock's PP&E (net) decreased by 45.6% year-over-year, from $2.64M to $1.44M.
What is the long-term trend for Scholar Rock's PP&E (net)?
Over 5 years (2020 to 2025), Scholar Rock's PP&E (net) has grown at a -26.8% compound annual growth rate (CAGR), from $8.12M to $1.71M.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.